Mesa and Ulmer Measure Methods for JAK Inhibitor Optimization in Myelofibrosis

November 19, 2020
OncLive Staff

Partner | Cancer Centers | <b>MD Anderson</b>

In our exclusive interview, Dr. Mesa and Dr. Ulmer discuss the current roles of ruxolitinib and fedratinib in myelofibrosis, current guidance for JAK inhibitor dosing, the utility of re-exposure to JAK inhibitors, and clinical trial options.

Welcome to OncLive On Air™! I’m your host today, Caroline Seymour.

OncLive On Air™ is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. 

In today’s episode, we had the pleasure of speaking with Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, and Scott Ulmer, MD, hematologist/oncologist at the START Center for Cancer Care, to discuss the optimization of JAK inhibitors in myelofibrosis.

In our exclusive interview, Mesa and Ulmer discuss the current roles of ruxolitinib (Jakafi) and fedratinib (Inrebic) in myelofibrosis, current guidance for JAK inhibitor dosing, the utility of re-exposure to JAK inhibitors, and clinical trial options.


x